Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com

Investment analysts at StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report released on Friday. The firm set a “sell” rating on the stock.

SYRS has been the topic of several other reports. Brookline Capital Management reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. JMP Securities reaffirmed a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright reissued a “neutral” rating and set a $1.00 price target (down from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Syros Pharmaceuticals has a consensus rating of “Hold” and an average target price of $3.33.

Syros Pharmaceuticals Trading Up 0.6 %

Shares of SYRS opened at $0.21 on Friday. Syros Pharmaceuticals has a 1-year low of $0.18 and a 1-year high of $7.96. The firm’s 50-day moving average price is $0.23 and its 200-day moving average price is $2.04. The firm has a market capitalization of $5.55 million, a price-to-earnings ratio of -0.07 and a beta of 1.31.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same period in the prior year, the firm earned ($1.35) EPS. On average, research analysts forecast that Syros Pharmaceuticals will post -2.94 EPS for the current fiscal year.

Insider Activity

In other news, Director Nancy A. Simonian sold 134,713 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $0.27, for a total value of $36,372.51. Following the transaction, the director now owns 41,070 shares in the company, valued at approximately $11,088.90. This represents a 76.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 12.26% of the company’s stock.

Hedge Funds Weigh In On Syros Pharmaceuticals

A hedge fund recently raised its stake in Syros Pharmaceuticals stock. Exome Asset Management LLC raised its stake in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 87.6% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 298,575 shares of the company’s stock after acquiring an additional 139,400 shares during the period. Exome Asset Management LLC owned approximately 1.11% of Syros Pharmaceuticals worth $642,000 as of its most recent SEC filing. 91.47% of the stock is owned by institutional investors and hedge funds.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.